Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sedana Medical AB's EBITDA for the
three
months ended in Jun. 2026 was kr-1.9 Mil. Sedana Medical AB's Revenue for the
three
months ended in Jun. 2026 was kr49.1 Mil. Therefore, Sedana Medical AB's EBITDA margin for the quarter that ended in Jun. 2026 was -3.85%.
Sedana Medical AB (OSTO:SEDANA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sedana Medical AB EBITDA Margin % Related Terms
Sedana Medical AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sedana Medical AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SEDANA vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Sedana Medical AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sedana Medical AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sedana Medical AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sedana Medical AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sedana Medical AB (OSTO:SEDANA) has a EBITDA Margin % of -3.85% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sedana Medical AB and its competitors. According to the industry distribution chart, Sedana Medical AB ranks #518 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 63.5%.
Is Sedana Medical AB's EBITDA Margin % too high?
Sedana Medical AB's current EBITDA Margin % is -3.85%. Based on the distribution chart, Sedana Medical AB ranks #518 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sedana Medical AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sedana Medical AB's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sedana Medical AB ranks #518 out of 816 companies for EBITDA Margin %. This places Sedana Medical AB in the lower half of its industry. The industry median EBITDA Margin % is 7.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sedana Medical AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sedana Medical AB's current EBITDA Margin % is -3.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sedana Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Sedana Medical AB (OSTO:SEDANA) is currently considered Significantly Undervalued. The stock's GF Value™ is kr17.42, compared to a current price of kr9.80 — trading 43.7% below its estimated fair value. The current EBITDA Margin % is -3.85%. Sedana Medical AB's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sedana Medical AB (OSTO:SEDANA), the current EBITDA Margin % is -3.85% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sedana Medical AB (OSTO:SEDANA) Overvalued in 2026?
Based on GuruFocus' analysis, Sedana Medical AB stock appears to be undervalued.
The current stock price of kr9.80 is trading 43.7% below its estimated GF Value™ of kr17.42.
GuruFocus considers Sedana Medical AB to be Significantly Undervalued.
Key valuation signals for OSTO:SEDANA:
EBITDA Margin %: -3.85%
GF Value™: kr17.42 vs. price of kr9.80 (43.7% below fair value)
No single metric tells the full story. See the OSTO:SEDANA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sedana Medical AB is a Sweden-based medical technology company. It is ais a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care. Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, and Spain. In other parts of Europe, as well as in Asia, Australia, Canada, and South and Central America, the company works with external distributors.
69GF Score
Get the complete analysis for OSTO:SEDANA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SEDANA has been successfully added to your 
